asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Tata Motors inaugurates ‘Customer Care Mahotsav’, a nationwide engagement program for commercial vehicle customers

by asianprimenews0566

Mumbai, 24 October 2024, Tata Motors, India’s largest commercial vehicle manufacturer, announced the launch of its Customer Care Mahotsav 2024, a comprehensive customer engagement program for commercial vehicle customers till 24th December, 2024. The unique and value adding programme will be held at over 2500 authorised service outlets across the country, bringing together fleet owners and drivers for insightful discussions. Through the Mahotsav, customers can avail a range of benefits, including thorough vehicle check-ups conducted by trained technicians, and access to value-added services. Additionally, drivers will receive extensive training on safe and fuel-efficient driving practices, along with tailored offerings under its Sampoorna Seva 2.0 initiative.

 

Launching the Customer Care Mahotsav 2024 edition, Mr. Girish Wagh, Executive Director, Tata Motors highlighted, “We are excited to bring back the Customer Care Mahotsav this year, starting 23rd October. The day holds a special significance for us as we sold our first commercial vehicle in 1954, we now celebrate it as the Customer Care Day. This Mahotsav reflects our commitment to deliver the best-in-class service, through meticulous vehicle check-ups and by offering a wide range of benefits. By ensuring that the Mahotsav delights our customers at every touchpoint across the country, we aim to strengthen our relationships across all our stakeholders. We cordially invite all our customers to their nearest Tata authorized service centres, and I am confident that this initiative will add significant value to their businesses.”

 

Tata Motors’ widest commercial vehicle portfolio is complemented by a host of value-added services designed for comprehensive vehicle lifecycle management through its Sampoorna Seva 2.0 initiative. This all-inclusive solution begins with the vehicle purchase and supports every operational aspect throughout its lifecycle, including breakdown assistance, guaranteed turnaround times, annual maintenance contracts (AMC), and convenient access to genuine spare parts. Additionally, Tata Motors leverages Fleet Edge, its connected vehicle platform for optimal fleet management, enabling operators to maximize vehicle uptime and minimize total cost of ownership.

Share

Related posts

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

GRIPIT Powers Amazon Prime Day with Global Tech Innovations for Indian Consumers

asianprimenews

Gustaakh Ishq to HAQ: Upcoming Bollywood Movies to Watch Out For in November

asianprimenews